StockData
Impact BioMedical Inc. logo

Impact BioMedical Inc. (IBO) stock

IBONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.06+0.38 (+14.18%)

Close on Oct 19, 2026Market cap $329.93MP/E –Yield –

Impact BioMedical operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Impact BioMedical's operating cash flow for the twelve months ending Jun 30, 2026 was -$508.00K. For fiscal 2025 it was -$1.89M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.89M–
FY2024Dec 31, 2024-$2.85M–
FY2023Dec 31, 2023-$2.85M–
FY2022Dec 31, 2022-$2.24M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$470.00K–
Q1 FY2026Mar 31, 2026-$464.00K–
Q4 FY2025Dec 31, 2025$99.00K–
Q3 FY2025Sep 30, 2025-$613.00K–
Q2 FY2025Jun 30, 2025-$694.00K–
Q1 FY2025Mar 31, 2025-$682.00K–
Q4 FY2024Dec 31, 2024-$986.00K–
Q3 FY2024Sep 30, 2024-$1.00M–
Q2 FY2024Jun 30, 2024-$385.00K–
Q1 FY2024Mar 31, 2024-$482.00K–
Q4 FY2023Dec 31, 2023-$433.00K–
Q3 FY2023Sep 30, 2023-$671.00K–
Q2 FY2023Jun 30, 2023-$733.00K–
Q1 FY2023Mar 31, 2023-$1.01M–
Q4 FY2022Dec 31, 2022-$363.00K–
Q3 FY2022Sep 30, 2022-$802.00K–

More Impact BioMedical figures

See a number that looks wrong?